Table 4.
Adverse events associated with the commercially available TKIs used in thyroid cancer.
| Adverse event | Sorafenib (%) | Sunitinib (%) | Pazopanib (%) | |||
|---|---|---|---|---|---|---|
| All grade | ≥grade 3 | All grade | ≥grade 3 | All grade | ≥grade 3 | |
| Hypertension | 17 | 4 | 30 | 12 | 40 | 4 |
| CHF or LVEF decline | 1.7 | NR | 13 | 3 | <1% | NR |
| Proteinuria | NR | NR | NR | NR | 9 | <1 |
| Hand-foot skin reaction | 30 | 6 | 29 | 6 | 6 | NR |
| Stomatitis | NR | NR | 30 | 1 | 4 | NR |
| Anorexia | 16 | <1 | 34 | 2 | 22 | 2 |
| Weight loss | 10 | <1 | 12 | <1 | 52 | 3.5 |
| Diarrhea | 43 | 2 | 61 | 9 | 52 | 3.5 |
| AST elevation | NR | NR | 56 | 2 | 53 | 7.5 |
| ALT elevation | NR | NR | 51 | 2.5 | 53 | 12 |
| Fatigue | 37 | 5 | 54 | 11 | 19 | 2 |
| Hypothyroidism | NR | NR | 14 | 2 | 7 | NR |
| Arterial thromboembolism | 2.9 | NR | NR | NR | 3 | 2 |
| Hemorrhage/bleeding (all sites) | 15 | 3 | 30 | 3 | 13 | 2 |
CHF: congestive heart failure; LVEF: left ventricular ejection fraction; AST: aspartate aminotransferase; ALT: alanine aminotransferase; NR: not reported. table adapted from [115].